Seoul-based medical equipment manufacturer Samsung Medison has recently finalized the acquisition of Sonio, a French company specializing in foetal ultrasound AI technology, for $92 million. Sonio, established four years ago, has developed innovative IT solutions tailored for obstetrics and gynaecology ultrasound procedures. Notably, Sonio Detect, its flagship product, has received FDA 510(k) clearance as the first machine-agnostic AI assistant software, streamlining ultrasound reporting and ensuring image quality control.
This acquisition underscores a broader industry trend where ultrasound system providers are integrating AI technology into their offerings. Samsung Medison's CEO, Yong Kwan Kim, envisions the collaboration with Sonio as a pivotal step towards revolutionizing prenatal ultrasound examinations. Sonio will retain its autonomy post-acquisition, continuing to operate independently from France. The deal is contingent upon regulatory approvals, including from the French Ministry of the Economy and Finance.
Sonio's strategic partnerships and funding efforts highlight its commitment to global expansion and technological advancement. Previously collaborating with Samsung Healthcare France and LifeCell, Sonio aims to penetrate markets across Asia and the United States. The company's successful Series A funding round of $14 million further supports its endeavors to enhance AI technology for portable ultrasound devices and point-of-care solutions, ensuring broader accessibility and improved healthcare outcomes worldwide.
Click here to read the original news story.